Wegovy® (semaglutide)
The following safety information is from the FDA-approved prescribing information for Wegovy® (semaglutide). It is provided for education only and is not a complete list of risks. Review it with your provider, who will determine whether this medication is clinically appropriate for you.
Warning: Risk of Thyroid C-Cell Tumors
- In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1), Nonclinical Toxicology (13.1)].
- WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications (4)]. Counsel patients regarding the potential risk for MTC with the use of WEGOVY and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with WEGOVY [see Contraindications (4), Warnings and Precautions (5.1)].
Warnings and Precautions (Selected)
Acute Pancreatitis; Acute Gallbladder Disease; Hypoglycemia in Patients with Type 2 Diabetes; Serious Hypersensitivity Reactions; Suicidal Behavior and Ideation; Pulmonary Aspiration During General Anesthesia or Deep Sedation.
Most Common Adverse Reactions (≥ 5%)
Nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis.
Reporting Suspected Adverse Reactions
To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc., at 1-833-934-6891 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Source: FDA-approved Wegovy® prescribing information, revised 08/2025. Full prescribing information (PDF). Wegovy® is a registered trademark of Novo Nordisk A/S. Get Well Clinic is not affiliated with, endorsed by, or sponsored by Novo Nordisk.